NERV Stock Summary and Trading Ideas (Minerva Neurosciences | NASDAQ:NERV)

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences trades on the NASDAQ stock market under the symbol NERV.

As of April 23, 2024, NERV stock price declined to $2.53 with 4,566 million shares trading.

NERV has a beta of 1.98, meaning it tends to be more sensitive to market movements. NERV has a correlation of 0.02 to the broad based SPY ETF.

NERV has a market cap of $17.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, NERV stock traded as high as $28.28 and as low as $1.26.

The top ETF exchange traded funds that NERV belongs to (by Net Assets): VTI, VXF.

NERV has underperformed the market in the last year with a return of +2.8%, while the SPY ETF gained +24.3%. In the last 3 month period, NERV fell short of the market, returning -67.4%, while SPY returned +4.6%. However, in the most recent 2 weeks NERV has outperformed the stock market by returning -0.4%, while SPY returned -2.6%.

NERV support price is $2.43 and resistance is $2.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NERV stock will trade within this expected range on the day.